

RESEARCH ARTICLE

Drosophila wing is a high-throughput and versatile screening tool for Tau-mediated disease mechanisms and drug discovery

Miguel Ramirez-Moreno^{1,*}, Amber S. Cooper¹, Tianshun Lian², Jie Liu², Seyedehleila Abtahi², Efthimios M. C. Skoulakis³, Lovesha Sivanantharajah⁴, Douglas Watt Allan^{2,*} and Amritpal Mudher^{1,*}

ABSTRACT

Tau protein contributes to microtubule stability, which is disrupted in Alzheimer's disease and other tauopathies. In these diseases, Tau molecules become hyperphosphorylated, misfolded and aggregated, propagating pathology across the brain. Studies dissecting disease mechanisms or screening disease-modifying therapies rely on animal models that unveil pathogenic events *in vivo* but also take several weeks or months to complete. Here, we describe a versatile experimental paradigm that yields results in days and yet offers all the advantages of a genetically tractable *in vivo* system: the *Drosophila* wing. Mimicking neurotoxicity, human Tau expression caused cell death in *Drosophila* wing disc, leading to quantifiable phenotypes in the adult wing. The neuroprotective peptide NAPVSIPQ ameliorated Tau toxicity in this system, validating it as a cost-effective drug-screening tool. Phenocopying adult neurons, Tau toxicity in the wing disc was exacerbated by simulating hyperphosphorylation and prevented by suppressing aggregation. Additionally, we showed that the wing disc can dissect disease mechanisms that underpin clinically relevant Tau variants. Thus, the *Drosophila* wing offers an *in vivo* experimental paradigm for fast and efficient exploration of disease mechanism and screening.

KEY WORDS: *Drosophila*, Wing, Wing disc, Neurodegeneration, Tau, Tauopathies

INTRODUCTION

The developing wing of the fruit fly, *Drosophila melanogaster*, is a well-established paradigm for growth, morphogenesis, regeneration and tumorigenesis (Tripathi and Irvine, 2022; Beira and Paro, 2016). The adult organ develops from the larval imaginal wing disc, an epithelial sac that, like the nervous system, is originated from the embryonic ectoderm. During metamorphosis, the two wing discs give rise to both parts of the thorax wall (notum region), the wing

hinge and the actual wing blade (Beira and Paro, 2016; Tripathi and Irvine, 2022). The wing discs are relatively flat structures more easily extractable than brains and can be cultured *ex vivo* for short periods (Moreno et al., 2022; Handke et al., 2014). Using established genetic tools [such as the Gal4/UAS system (Brand and Perrimon, 1993)], fly researchers can express genes of interest, and their ensuing protein products, within finite anatomically defined regions of the wing disc that can be traced to distinct regions of the adult wing (Tripathi and Irvine, 2022). Tractable genetic lineages divide the organ into compartments (anterior/posterior or dorsal/ventral), so researchers can target expression of genes of interest to specific compartments of the organ while using the other compartments as an internal experimental control within the same sample (Tabata et al., 1995; Brand and Perrimon, 1993). This highly accessible system lends itself to all manner of studies relevant to disease modelling, from dissecting disease mechanisms to candidate drug screening assays, all of which can be done in a week. This offers a great first-pass model system to streamline the design of long-term assays in more clinically-relatable paradigms such as the adult nervous system, which require significantly longer experimental times.

Dementia is currently one of the most pressing health challenges worldwide, with the most common cause being Alzheimer's disease. The pathological hallmarks of Alzheimer's disease include the aberrant accumulation and dysfunction of the microtubule-associated protein Tau (also known as MAPT) (Weingarten et al., 1975; Alzheimer, 1907; Parra Bravo et al., 2024). Under normal physiological conditions, Tau regulates the neuronal cytoskeleton; but, in disease states, it accumulates to form aggregates such as neurofibrillary tangles within the brain (Tabeshmehr and Eftekharpour, 2023; Goedert et al., 2023; Drechsel et al., 1992; Kanaan, 2023). Other neurodegenerative diseases characterized by Tau dysfunction, such as frontotemporal lobar degeneration, progressive supranuclear palsy or Pick's disease, are collectively termed as tauopathies (Zempel et al., 2017). A series of extrinsic and intrinsic factors, from the cellular environment to the Tau protein itself, contributes to its transition from a physiological to pathological state (Morris et al., 2011; Kanaan, 2023; Goedert and Jakes, 2005). Pathological features of Tau include abnormal phosphorylation (hyperphosphorylation), mislocalization, conformational changes and aggregation, occurring in a cascade of events leading to neurofibrillary tangles (Buchholz and Zempel, 2024a; Alonso et al., 2001; Cowan et al., 2010; Stoothoff and Johnson, 2005; Kimura et al., 2018; Wegmann et al., 2021). It is important to investigate why Tau becomes pathological and how it impacts affected cells; and, to address this question, many successful experimental paradigms of neurodegeneration have been established. However, most of these models examine Tau pathology in ageing nervous systems, which often require significant time and resources – sometimes taking several years as with rodent models. Even

¹School of Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK. ²Department of Cellular and Physiological Sciences, Life Science Institute, University of British Columbia, Vancouver V6T 1Z3, Canada. ³Institute for Fundamental Biomedical Research, Biomedical Sciences Research Centre "Alexander Fleming", Vari 16672, Greece. ⁴School of Biological Sciences, Bangor University, Bangor LL57 2UW, UK.

*Authors for correspondence (M.Ramirez-Moreno@soton.ac.uk; doug.allan@ubc.ca; A.Mudher@soton.ac.uk)

 M.R.-M., 0000-0003-1559-8976; A.S.C., 0000-0003-2525-0148; S.A., 0000-0003-3672-3705; E.M.C.S., 0000-0001-5113-6192; L.S., 0009-0009-5160-2697; D.W.A., 0000-0002-3488-8365; A.M., 0000-0002-0880-1107

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

Handling Editor: Steven J. Clapcote
Received 20 May 2025; Accepted 26 January 2026

short-lived invertebrate models, such as *Drosophila* (Cowan et al., 2011; Sivanantharajah et al., 2019), have limitations for large-scale screenings as neurodegeneration requires weeks to manifest (Table S1). Although two- or three-dimensional cell culture models can be faster, they are *in vitro* experimental paradigms that fail to fully reproduce the complexity of animal brains and are prone to other technical issues, such as inefficient transfection, that could affect the reproducibility of assays.

Thus, we need a fast and versatile *in vivo* platform that combines the ability to dissect cellular pathways with a superior and efficient spatiotemporal genetic tractability. In this study, we validate the developing wing of *Drosophila* as a new tool that meets all these criteria. This experimental paradigm takes advantage of the extensive genetic toolkit of *Drosophila* and, as described in this work, can provide a fast, highly efficient and relevant system for the interrogation of Tau-mediated disease mechanisms and drug screening. In this system, the expression of human Tau isoforms triggers an apoptotic response in the wing disc, which correlates with the severity of observed phenotypes in the adult organism. We recapitulated several aspects of Tau-mediated toxicity that have been described in the adult central nervous system, highlighting the potential of the wing disc experimental paradigm to study the impacts of Tau on cellular pathways. The extensive use of the wing disc to study cell biology (Moreno et al., 2022), and especially intracellular trafficking processes implicated in Tau toxicity (Yan and Zheng, 2021; Rauch et al., 2020), represents a further advantage of this platform. Additionally, we show the capacity of this model to rescue Tau phenotypes using drugs that have been shown to be effective against Tau-mediated neurotoxicity in rodent models, validating the use of the *Drosophila* wing for drug discovery and screening.

RESULTS

***Drosophila* wing disc and adult wing are a fast and robust scorable paradigm to quantify Tau toxicity**

In early embryogenesis, cells and tissues of the developing fly acquire identities that separate them into developmental compartments, delimited by boundaries of cells and lineages (Garcia-Bellido et al., 1973; Tabata et al., 1995). The Gal4/UAS system allows to specifically target, for example, the posterior compartment, constituted by *engrailed*-expressing cells (*en*-Gal4), leaving the anterior compartment as internal control (Fig. 1A) (Tabata et al., 1995; Brand and Perrimon, 1993). A change in the relative contribution of the posterior compartment to the total disc size (as measured with the posterior/anterior ratio, see Materials and Methods) allows the detection of growth/developmental anomalies at the targeted tissue (Moreno et al., 2022), while accounting for differences in absolute size due to diet or genetic background. We expressed mCherry-tagged (mCh::) copies of two 4R isoforms of human Tau (indicated as ‘hTau’): hTau0N4R and hTau2N4R (Corsi et al., 2022; Mandelkow and Mandelkow, 2012; Parra Bravo et al., 2024), which were inserted into the same chromosomal site (AttP40) to minimize background differences. Tissues with expression of human Tau isoforms were compared to tissues with expression of mCherry protein alone, which caused no known deleterious effects (Fig. 1B) (Moreno et al., 2022). Both human Tau isoforms led to a morphological change in the wing disc, reducing the size of the posterior compartment (Fig. 1B,C). Unexpectedly, hTau0N4R caused a stronger effect than the full-length hTau2N4R isoform (Fig. 1C). Flies expressing either isoform of human Tau at their posterior compartments reached adulthood with no developmental delay or detectable anatomical defects elsewhere,

but those expressing hTau0N4R displayed a marked reduction of the posterior region of the adult wing, identified as the area below the vein L4 (Fig. 1A,D,E). Alongside the reduced size, many of the hTau0N4R-expressing compartments displayed notched margins (Fig. 1D). In comparison, the milder wing disc phenotype in hTau2N4R-expressing individuals was compensated by the organ and did not manifest after metamorphosis (Fig. 1D,E), indicating that the baseline insult due to full-length hTau2N4R expression can be compensated by the wing disc tissue.

With such effects at the adult wing blade, we analysed cell death in the wing disc pouch – the region from which it originates during metamorphosis – because apoptosis is a well-known consequence of human Tau expression in the *Drosophila* central nervous system (Dias-Santagata et al., 2007; Abreha et al., 2021; Gistelink et al., 2012). To assess the amount of apoptosis at the wing disc, which is occasional but sparse during normal development, we analysed the signal of cleaved effector caspase Dcp-1, one of the caspase-3-like proteins of *Drosophila* and downstream effector of apoptosis (Fig. 2A) (Song et al., 1997), at the basal region of the discs from which dying cells are extruded from the tissue (Moreno et al., 2022; Bergantiños et al., 2010; Matamoro-Vidal et al., 2024) (Fig. 2B). The pouch region of each compartment was identified using anatomical and fluorescence markers delineating its boundaries (Fig. 2C). Although the expression of mCherry alone did not trigger apoptosis, expression of both human Tau isoforms led to significant apoptosis in the posterior compartment (Fig. 2C,D). The stronger phenotype upon hTau0N4R expression was consistent with the more pronounced tissue-level phenotypes at larval and adult stages (Fig. 1), thus correlating the reduced compartment size with apoptosis activation and cell death.

JNK signalling is responsible for the release of multiple signals in the developing wing disc, including apoptosis and compensatory proliferation following stress (Pérez-Garijo et al., 2009; Moreno et al., 2022; Pinal et al., 2019). JNK signalling can be tracked with the expression of *puckered* (*puc*), which encodes a negative regulator that acts as negative feedback upon pathway activation (Fig. 2A) (Martín-Blanco et al., 1998; Ring and Martínez Arias, 1993). We used the *pucE69-lacZ* construct to drive expression of β -galactosidase (Ring and Martínez Arias, 1993) and found that overexpression of hTau0N4R, but not hTau2N4R, was sufficient to cause tissue-wide upregulation of JNK signalling (Fig. 2E,F). Consistently, upregulation of the JNK signalling pathway at the posterior compartment could induce a small but discernible non-cell autonomous apoptotic response at the anterior compartment (Diaz-Garcia et al., 2016), much like observed in discs with high levels of apoptosis (Pérez-Garijo et al., 2013) and in some hTau0N4R-expressing discs (Fig. 2C). Overall, we found that the expression of human Tau induces toxicity in the developing wing disc, which is akin to Tau-induced neurotoxicity and can be quantified with multiple readouts in both the larval discs and adult wing.

***Drosophila* wing can be used for testing drugs counteracting Tau toxicity**

As the generation of disease-modifying treatments represents one of the biggest challenges faced by dementia researchers and having a high-throughput drug screening platform is highly desirable, we asked whether the Tau-induced cytotoxicity at the wing disc could be ameliorated using drug treatments. Previous studies have highlighted the neuroprotective properties of the octapeptide NAPVSIQ (NAP; davunetide), an active component of activity-dependent neuroprotective protein (ADNP), essential for mammalian brain




Fig. 1. Human Tau expression reduces the compartment size at the *Drosophila* wing. (A) Cartoon depicting the developing third-instar larvae [6 days after egg laying (AEL)] and *Drosophila* adult organism, with views of the developing imaginal wing disc (top) and adult wing (bottom). Cells corresponding to the posterior compartment are highlighted in magenta, and the circle highlights the disc pouch, from which the adult wing blade originates during metamorphosis. (B) Wing discs expressing *mCD8::Cherry* (left) or *mCherry*-tagged (*mCh::*) human Tau (indicated as 'hTau') isoforms, showing *mCherry* (*Cherry*; magenta, top; grayscale, bottom) and *E-cadherin* (*E-cad*) antibody (green, top) signal, with anterior (A) and posterior (P) compartments. Scale bar: 100 μ m. (C) Posterior/anterior ratios of control (*mCD8::Cherry*) and *mCh::hTau*-expressing wing discs. Dots represent individual discs; median and interquartile ranges are shown ($n=29$, 15 and 28; three independent crosses). ns, not significant; ** $P<0.01$ and *** $P<0.001$ (Kruskal–Wallis test). Both 0N4R and 2N4R isoforms significantly reduce compartment size when compared to the control. (D) Adult wings (grayscale) expressing *mCD8::Cherry* (top) or *mCh::hTau* isoforms, showing a magenta overlay of the approximated posterior compartment (below L4). Scale bar: 0.5 mm. (E) Posterior/anterior ratios of adult wings expressing *mCD8::Cherry* or *mCh::hTau* isoforms during development. Dots represent individual wings/adults; median and interquartile ranges are shown ($n=20$, 20 and 18; three independent crosses). **** $P<0.001$ (Kruskal–Wallis test).

development (Bassan et al., 1999; Gozes et al., 2005). Indeed, we previously reported that administration of NAP in the diet was sufficient to improve phenotypes associated with human Tau expression in the nervous system, including defects in larval locomotion and axonal transport (Quraishe et al., 2013, 2016). To test whether diet-administered NAP would reach the imaginal tissue as well, we raised flies expressing hTau0N4R at their posterior compartments with the peptide dissolved in the food. We confirmed that none of the NAP dosages produced detrimental effects in *mCherry*-expressing wing discs or adult wings (Fig. S1), nor did they increase the apoptotic rate across the entire wing disc pouch (Fig. S1C,D). The improvement of the tissue-level phenotype was undiscernible in the wing discs when presented alongside *mCherry*-expressing controls (Fig. 3A,B). However, 5 μ g/ml NAP reduced the apoptotic rate (Fig. 3C,D). NAP administration improved the morphology of the adult wing again in the small concentration sample (Fig. 3E,F), while the high dose (25 μ g/ml) caused a striking bi-modal distribution of adult

wings, with some of them displaying almost wild type-like wings. As the high dosage of NAP did not reduce the apoptotic rate in the wing disc and changed the data distribution in the adult wings but was, at the same time, harmless to control individuals (Fig. S1), synergistic effects between excess NAP and Tau may be occurring. Therefore, the improvement of the phenotypes caused by hTau0N4R expression highlight the potential of the wing disc as a drug screening tool for finding mediators and inhibitors of Tau-derived toxicity.

***Drosophila* wing can be used to genetically dissect novel mechanisms of Tau toxicity**

So far, we had characterized the baseline toxic response caused by human Tau expression at the developing wing, and its sensitivity to drug treatments. We next asked whether pathogenic features of human Tau such as aggregation or hyperphosphorylation, could be targeted to modify its toxicity in this system. Regarding aggregation, two hexapeptide motifs (VQ domains) inside the microtubule-




Fig. 2. Human Tau expression induces apoptotic response at the wing disc. (A) Simplified scheme of the *Drosophila* apoptotic pathway. Briefly, pro-apoptotic factors activate, among others, JNK [Basket (Bsk), the *Drosophila* homologue] signalling, which, in turn, promotes the expression of activator caspases such as *reaper* (*rpr*) and the expression of the negative regulator *puckered* (*puc*). Initiator caspases inhibit *Drosophila* Diap1, which respectively inactivates Dronc (*Drosophila* homologue of caspase-9). Dronc then cleaves effector caspase-3 like proteins such as Dcp-1 and Drice. (B) Wing pouches expressing mCD8::Cherry (left) or mCherry-tagged (mCh::) human Tau isoforms, showing cleaved Dcp-1 antibody (green, top and middle rows; grayscale, bottom sagittal projection), mCherry (magenta, top and middle rows) expressed at the posterior compartment (P) and E-cadherin antibody (white, top and middle rows) signal. Sagittal views at the bottom represent a projection of 3.78 μ m at the 'Y' position of the blue dashed line in top panel. Scale bars: 25 μ m. (C) Wing pouches expressing mCD8::Cherry (left) or mCherry-tagged (mCh::) human Tau isoforms, showing cleaved Dcp-1 antibody (green, top row; grayscale, bottom row) and mCherry (magenta, top row) signal. Magenta dashed lines in the bottom row indicate the anterior–posterior compartment boundary. Scale bar: 50 μ m. (D) Excess apoptotic area at the posterior compartment for the indicated genotypes. Dots represent individual discs; median and interquartile ranges are shown ($n=19, 13$ and 15 ; three independent crosses). ns, not significant; ** $P<0.01$, *** $P<0.001$ and **** $P<0.0001$ (Brown–Forsythe and Welch ANOVA test for multiple comparisons, and one-sample *t*-test in comparison to zero for random distribution of apoptosis). (E) Apical region of dorsal wing pouch cells expressing mCD8::Cherry (left) or mCherry-tagged (mCh::) human Tau isoforms alongside the *puc-lacZ* sensor, showing β -galactosidase antibody (β -gal; green, top row; grayscale, bottom row) and mCherry (magenta, top row) signal. Magenta dashed lines in the bottom row indicate the anterior–posterior compartment boundary. Scale bar: 10 μ m. (F) Posterior/anterior ratio of β -galactosidase antibody in dorsal wing pouch cells. Dots represent individual discs; median and interquartile ranges are shown ($n=13, 11$ and 10 ; two independent crosses). ns, not significant; ** $P<0.01$ and **** $P<0.0001$ (Kruskal–Wallis test).

binding domain (MTBD), ²⁷⁵VQIINK²⁸⁰ and ³⁰⁶VQIVYK³¹¹, are of special interest as they comprise the core of the pathological Tau fibrils (Wu et al., 2022; von Bergen et al., 2000). Recently, we

showed that the deletion of the ³⁰⁶VQIVYK³¹¹ aggregation motif was sufficient to render human Tau inert in the ageing *Drosophila* nervous system (Cooper et al., 2024 preprint).




Fig. 3. NAPVSIPQ peptide partially rescues human Tau toxicity in the *Drosophila* wing. (A) Wing discs expressing mCD8::Cherry (left column) or mCherry-tagged (mCh::) hTau0N4R corresponding to individuals treated with NAPVSIPQ (NAP) peptide, showing mCherry signal (magenta, top row; grayscale, bottom row) and E-cadherin staining (green, top row). Scale bar: 100 µm. (B) Posterior/anterior ratios of mCD8::Cherry-expressing and NAP-treated, mCh::hTau0N4R-expressing wing discs. Dots represent individual discs; median and interquartile ranges are shown ($n=14, 16, 17$ and 15 ; three independent crosses). ns, not significant (Brown–Forsythe and Welch’s ANOVA test). (C) Wing pouches expressing mCD8::Cherry (left column) or mCh::hTau0N4R corresponding to individuals treated with NAP peptide, showing cleaved Dcp-1 antibody (green, top row; grayscale, bottom row) and mCherry (magenta, top row). Magenta dashed lines in the bottom row indicate the anterior–posterior compartment boundary. Scale bar: 50 µm. (D) Excess apoptotic area at the posterior compartment for the indicated genotypes and treatments. Dots represent individual discs; median and interquartile ranges are shown ($n=15, 16, 18$ and 15 ; three independent crosses). ns, not significant; $*P<0.05$, $**P<0.01$ and $****P<0.0001$ (Kruskal–Wallis test for multiple comparisons, and one-sample Wilcoxon test in comparison to zero for random distribution of apoptosis). (E) Adult wings (grayscale) of mCD8::Cherry-expressing (left) or NAP-treated flies expressing mCh::hTau0N4R during development, showing a magenta overlay of the approximated posterior compartment (below L4). Scale bar: 0.5 mm. (F) Posterior/anterior ratios of adult wings expressing mCD8::Cherry (left) or mCh::hTau0N4R and treated with NAP during development. Dots represent individual wings/adults; median and interquartile ranges are shown ($n=21, 32, 23$ and 72 ; four independent crosses). ns, not significant; $*P<0.05$, $**P<0.01$ and $****P<0.001$ (Kruskal–Wallis test).

We sought to test whether the capacity for self-aggregation was a contributor to toxicity at the wing disc and whether phosphorylation would also increase toxicity in this system as well. We first tested the effects of deleting the $^{306}\text{VQIVYK}^{311}$ domain (ΔVQIVYK), one of the two aggregation promoting motifs shown to have the highest propensity for aggregation *in vitro* (Ganguly et al., 2015). To do so, we introduced the sequence change in the hTau0N4R isoform independently, as it produces the strongest response in the wing (Fig. 1). We found that hTau0N4R $^{\Delta\text{VQIVYK}}$ completely rescued the phenotype at both cell and tissue levels in the wing disc, effectively eliminating the Tau-mediated toxicity and rendering it

indistinguishable from the expression of mCherry tag alone in the same insertion cassette as the Tau tools (Fig. 4B,D,F). To obtain more information regarding the mechanisms of human Tau-induced toxicity, we simulated hyperphosphorylation with the E14 variant, which carries 14 serine/threonine to glutamate substitutions in residues linked to pathology, resulting in a phosphomimic protein with increased neurotoxicity in multiple models (Hatch et al., 2017; Steinhilb et al., 2007; Cooper et al., 2024 preprint; Hoover et al., 2010). hTau0N4R $^{\text{E14}}$ exacerbated the toxic response (Fig. 4), causing a massive apoptotic response and a further reduction of the posterior compartment at the adult wing (Fig. 4B,D,F).




Fig. 4. Aggregation and phosphorylation modify 0N4R-induced phenotypes. (A) Wing discs expressing mCherry (left column) or mCherry-tagged (*mCh::*) variants of the original hTau0N4R isoform (WT; second column), showing mCherry signal (magenta, top row; grayscale, bottom row) and E-cadherin staining (green, top row). Scale bar: 100 μ m. (B) Posterior/anterior ratios of wing discs expressing *mCD8::Cherry* or *mCh::hTau0N4R* variants, showing design combinations at the bottom of the table. Dots represent individual discs; median and interquartile ranges are shown ($n=14, 14, 12$ and 25 discs; two independent crosses for mCherry; three independent crosses for the rest). ns, not significant; * $P<0.05$ and *** $P<0.001$ (Kruskal–Wallis test). (C) Wing pouches expressing mCherry or *mCh::hTau0N4R* variants, showing cleaved Dcp-1 antibody (green, top row; grayscale, bottom row) and mCherry (magenta, top row) signal. Magenta dashed lines in the bottom row indicate the anterior–posterior compartment boundary. Scale bar: 50 μ m. (D) Excess apoptotic area at the posterior compartment for the indicated genotypes. Dots represent individual discs; median and interquartile ranges are shown ($n=16, 17, 12$ and 26; two independent crosses for mCherry; three independent crosses for the rest). ns, not significant; * $P<0.05$, ** $P<0.01$ and **** $P<0.0001$ (Kruskal–Wallis test and one-sample Wilcoxon test comparison to zero for random distribution of apoptosis). (E) Adult wings (grayscale) expressing mCherry or *mCh::hTau0N4R* variants, showing a magenta overlay of the approximated posterior compartment (below L4). Scale bar: 0.5 mm. (F) Posterior/anterior ratios of adult wings expressing mCherry or *mCh::hTau0N4R* variants during development. Dots represent individual wings/adults; median and interquartile ranges are shown ($n=18, 13, 16$ and 14; two independent crosses for mCherry; three independent crosses for the rest). ns, not significant; **** $P<0.0001$ (Kruskal–Wallis test).

We next tested a panel of hTau2N4R variants (see Fig. 6) to confirm the findings obtained with hTau0N4R (Fig. 4) and to compare the effect of $\Delta VQIVYK$ with that of deletion of the second aggregation motif, $^{275}VQIINK^{280}$ ($\Delta VQIINK$). VQIINK is a hexapeptide with stronger intrinsic self-aggregation capacity than VQIVYK but is more dispensable in the Tau pathological cascade (Seidler et al., 2018; Passarella and Goedert, 2018). Both hTau2N4R $^{\Delta VQIVYK}$ and hTau2N4R $^{\Delta VQIINK}$ produced similar rescue of hTau2N4R-induced toxicity (Fig. 5A–D; Table S2). In contrast, the E14 substitutions (hTau2N4R E14) did not ostensibly impact the size of the developing posterior compartment (Fig. 5A,C) but triggered a strong apoptotic response in the posterior pouch

(Fig. 5B,D). We then assessed the impact of independently deleting the two aggregation motifs on the E14 wing phenotypes, following our discovery that hTau2N4R $^{E14,\Delta VQIVYK}$ is an inert protein unable to drive neurodegeneration in the fly (Cooper et al., 2024 preprint). We recapitulated the total rescue of the E14 variant in the developing wing with hTau2N4R $^{E14,\Delta VQIVYK}$; but, strikingly, hTau2N4R $^{E14,\Delta VQIINK}$ failed to completely abrogate the cytotoxic response of the E14 variant (Fig. 5A–D; Table S2). The results of these variants at the adult wing reproduced those in the wing discs, with hTau2N4R E14 manifesting a marked phenotype at the targeted compartment that was, again, rescued by the two deletions but only completely by $\Delta VQIVYK$ (Fig. 5E,F).




Fig. 5. Human Tau requires the VQIVYK motif to drive toxicity at the developing wing. (A) Wing discs expressing variants (rows) of the original mCherry-tagged (mCh::) hTau2N4R isoform (WT; top row), showing mCherry signal (magenta, left column; grayscale, right column) and E-cadherin staining (green, left column). Scale bar: 100 μ m. (B) Wing pouches expressing mCh::hTau2N4R variants, showing cleaved Dcp-1 antibody (green, left column; grayscale, right column) and mCherry (magenta, left column) signal. Magenta dashed lines in the right column indicate the anterior–posterior compartment boundary. Scale bar: 50 μ m. (C) Posterior/anterior ratios of wing discs expressing mCherry or mCh::hTau2N4R variants, showing design combinations at the bottom of the table. Dots represent individual discs; median and interquartile ranges are shown ($n=9, 16, 21, 14, 16, 15$ and 13 discs; two independent crosses for mCherry; three independent crosses for the rest). $*P<0.05$ and $***P<0.001$ (Brown–Forsythe and Welch ANOVA test). Only multiple comparisons from the Brown–Forsythe and Welch ANOVA test that reached statistical significance ($P<0.05$) are shown. All pairwise comparisons (Student’s or Welch’s t -tests) are provided in Table S2. (D) Excess apoptotic area at the posterior compartment for the indicated genotypes. Dots represent individual discs; median and interquartile ranges are shown ($n=13, 19, 21, 16, 17, 19$ and 17 ; two independent crosses for mCherry; three independent crosses for the rest). $*P<0.05$, $**P<0.01$, $***P<0.001$ and $****P<0.0001$ (Kruskal–Wallis, and one-sample Wilcoxon test comparison to zero for random distribution of apoptosis). Only multiple comparisons from the Kruskal–Wallis test that reached statistical significance ($P<0.05$) are shown. All pairwise comparisons (t -tests or Mann–Whitney U -tests) are provided in Table S2. (E) Adult wings (grayscale) expressing mCh::hTau2N4R variants (presence/deletion of aggregation motifs, rows; inclusion of phosphomimetic E14 substitutions, columns), showing a magenta overlay of the approximated posterior compartment (below L4). Scale bar: 0.5 mm. (F) Posterior/anterior ratios of adult wings expressing mCherry or mCh::hTau2N4R variants during development. Dots represent individual wings/adults; median and interquartile ranges are shown ($n=22, 19, 23, 24, 22, 28$ and 21 ; two independent crosses for mCherry; three independent crosses for the rest). $***P<0.001$ and $****P<0.0001$ (Kruskal–Wallis test). Only multiple comparisons from the Kruskal–Wallis test that reached statistical significance ($P<0.05$) are shown. All pairwise comparisons (t -tests or Mann–Whitney U -tests) are provided in Table S2.

Altogether, these assays demonstrate that the *Drosophila* wing is a valid paradigm to study disease mechanisms associated with Tau-mediated toxicity. We tested this hypothesis by recapitulating our results in the ageing nervous system (Cooper et al., 2024 preprint), confirming that the ³⁰⁶VQIVYK³¹¹ motif is essential for human Tau to be toxic in this system as well, independently of the presence of pathology-prone phosphomimic substitutions. We also found that deletion of ²⁷⁵VQIINK²⁸⁰ failed to completely rescue the

hypertoxic effects of the E14 substitutions, thus using our new platform obtained new *in vivo* evidence of the differential contribution of both aggregation motifs to Tau toxicity.

The wing disc can be used to study clinical variants of interest

We next sought to investigate whether our experimental paradigm could be used to study the toxicity of clinically relevant variants and unpick the underlying mechanisms of their toxicity. We




Fig. 6. The wing disc allows the screening of point mutations in the human Tau sequence. (A) Wing discs expressing mutant variants (columns) of the original mCherry-tagged (mCh::) hTau2N4R (WT; left), showing mCherry signal (magenta, top row; grayscale, bottom row) and E-cadherin staining (green, top row). Scale bar: 100 μ m. (B) Posterior/anterior ratios of wing discs expressing mCh::hTau2N4R mutations, showing design combinations at the bottom of the plot. Dots represent individual discs; median and interquartile ranges are shown ($n=19, 13, 18$ and 18 ; three independent crosses). ns, not significant (Brown–Forsythe and Welch ANOVA test). All pairwise comparisons (Student’s *t*-tests) are provided in Table S3. (C) Wing pouches expressing mCh::hTau2N4R mutations, showing cleaved Dcp-1 antibody (green, top row; grayscale, bottom row) and mCherry (magenta, top row) signal. Magenta dashed lines in the bottom row indicate the anterior–posterior compartment boundary. Scale bar: 50 μ m. (D) Excess apoptotic area at the posterior compartment for the indicated genotypes. Dots represent individual discs; median and interquartile ranges are shown ($n=19, 16, 18$ and 20 ; three independent crosses). ns, not significant; ** $P<0.01$ and **** $P<0.0001$ (Kruskal–Wallis test, and one-sample Wilcoxon test comparison to zero for random distribution of apoptosis). All pairwise comparisons (*t*-tests or Mann–Whitney *U*-tests) are provided in Table S3. (E) Adult wings (grayscale) expressing mCh::hTau2N4R mutations, showing a magenta overlay of the approximated posterior compartment (below L4). Scale bar: 0.5 mm. (F) Posterior/anterior ratios of adult wings expressing mCh::hTau2N4R during development. Dots represent individual wings/adults; median and interquartile ranges are shown ($n=18, 19, 23$ and 20 ; three independent crosses). ns, not significant; * $P<0.05$ and *** $P<0.001$ (Brown–Forsythe and Welch ANOVA test). All pairwise comparisons (Student’s or Welch’s *t*-tests) are provided in Table S3.

chose R406W, one of the many mutations linked to frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), a dominantly inherited early onset form of dementia (Wittmann et al., 2001; Hutton et al., 1998; Goedert and Jakes, 2005).

In line with previous reports from *Drosophila* models expressing hTau2N4R^{R406W} in the ageing nervous system, we found a stronger toxic response to this variant than to hTau2N4R (Fig. 6). This was abrogated by the additional substitution of S262 and S356, two targets of microtubule affinity-regulating kinase (MARK)/Par-1 kinase (Chatterjee et al., 2009) to alanine (hTau2N4R^{S2A}), which renders them non-phosphorylatable, in the same protein (Fig. 6C,D). In the adult wings, examination of all the genotypes together indicated that expression of both S2A mutants (alone or alongside R406W) produced bigger posterior compartments than R406W alone (Fig. 6E,F), whereas no obvious effects on tissue size were found with R406W, unlike with the E14 variant (Fig. 5). Compared with discs expressing hTau2N4R, hTau2N4R^{R406W}-expressing wings discs had increased apoptotic response at their posterior compartment ($P=0.0159$) and affected adult wings ($P=0.0295$) (Table S3). Importantly, we found that the S2A substitutions alone reduced the apoptotic response caused by hTau2N4R (Fig. 6C,D; Table S3). These results indicate that the two Par-1 phosphorylation targets of human Tau sequence are major contributors to Tau toxicity at the wing disc. Furthermore, as exemplified by R406W mutation, the wing disc allows for the discrimination of point mutations, even with simple readouts as the analysis of the adult wing using developmentally robust region cues such as the veins. In turn, the wide range of disease factors related to Tau protein that can be recapitulated at the developing wing of the fly certifies the promising usage of this system as a screening tool to aid *Drosophila* biologists and non-fly researchers alike in the discovery of disease mechanisms and windows to target them.

DISCUSSION

The current work assessed the potential of the *Drosophila* wing to serve as a platform to dissect human Tau toxicity and the diverse mechanisms that underpin it. We show that in our system it is possible to recapitulate the cellular damage caused by human Tau in fly and rodent models of neurodegeneration (Figs 1 and 2). Importantly, clinically relevant mechanisms of toxicity – hyperphosphorylation and aggregation – identified in both invertebrate and vertebrate neurons also drive human Tau toxicity in the *Drosophila* wing (Figs 4 and 5). Furthermore, the administration of neuroprotective compounds that counteract Tau-mediated neurodegeneration in rodent models of tauopathy suppressed human Tau toxicity in the *Drosophila* wing, validating its utility as a drug discovery tool (Fig. 3). Finally, the wing can also be used to interrogate familial human Tau variants, underscoring its potential to study human Tau variants of unknown clinical significance (Fig. 6). Taken together, we propose that the *Drosophila* wing is a powerful and accessible experimental paradigm yielding results consistent with those from neuronal models. Thus, it serves as a dependable and economical alternative to rapidly dissect disease mechanisms and perform high-throughput genetic/pharmacological screening.

The wing disc is a robust tool to study Tau toxicity

Our study, focused on dissecting disease mechanisms underpinning tauopathies, further highlights the usefulness of the *Drosophila* wing system in this area of research. Our results are consistent with reported effects attributed to hTau0N4R expression at the *patched* domain of the wing (Bougé and Parmentier, 2016). Others have additionally found that the wing cells are sensitive to the expression

of amyloid β 2 and the dysregulation of its precursor protein (Fossgreen et al., 1998; Arnés et al., 2017). The wing has also been successfully employed to model disease mechanisms and identify novel modifiers of C9orf72 and TDP-43 (also known as TARDBP) (Lopez-Gonzalez et al., 2019; Yusuff et al., 2023).

Our observations suggest that ectopic cell apoptosis is the main consequence of human Tau-mediated toxicity in the wing. Apoptosis in cells undergoing neurodegeneration has been linked to an attempt to re-enter the cell cycle (Frost, 2023; Cotman and Anderson, 1995; Troy and Jean, 2015; Khurana and Feany, 2007). Furthermore, Tau dysregulation has been linked to both promotion and inhibition of apoptosis (Li et al., 2007; Cimini et al., 2022). Human Tau expression in animal models including *Drosophila* lead to increased apoptosis in the brain (Abreha et al., 2021; Gistelink et al., 2012), and this response is enhanced by the presence of the R406W and E14 substitutions (Dias-Santagata et al., 2007), much like we observe in the *Drosophila* wing system. The most direct connection between Tau and apoptosis links DNA damage with the tumour suppressor p53 protein, which also controls the apoptotic response in *Drosophila* (Hooper et al., 2007; Sola et al., 2020; Farmer et al., 2020; Asada-Utsugi et al., 2022). Although flies lack the negative p53 regulator MDM2 (which is functionally replaced by the *Drosophila* Corp), it is known that p53 promotes Tau phosphorylation levels, acting as a positive feedback for neurodegeneration (Jazvinšćak Jembrek et al., 2018; Hooper et al., 2007; Chakraborty et al., 2015).

Intriguingly, we found a difference in the intrinsic toxicity of the 0N4R and 2N4R isoforms (Figs 1, 4 and 5). Compared to the studies exploring the MTBD-related differences between 3R and 4R isoforms, the effects of the N repeats in the N-terminal region remain less explored, as many of the disease-relevant residues are common across all six isoforms (Cario et al., 2022; Kanaan et al., 2012). The different number of N repeats, resulting from alternative splicing affecting exons 2 and 3 (Goedert et al., 1989; Goedert and Jakes, 2005; Buchholz and Zempel, 2024a), has been linked to subcellular location differences (somatic versus axonal accumulation) (Zempel et al., 2017; Bachmann et al., 2021; Liu and Götz, 2013), affinity for binding partners (Liu et al., 2016; Buchholz and Zempel, 2024a) and opposing effects in promoting self-aggregation (Zhong et al., 2012). Although hTau0N4R and hTau2N4R display the same affinity for tubulin *in vitro* (Goode et al., 2000), the varying lengths of the N-terminal region may impact the ability of Tau to space microtubule bundles or cause crowding (Chung et al., 2016; Méphon-Gaspard et al., 2016; Prezel et al., 2018). Collectively, these differences in the physiological properties of the six human Tau isoforms may be responsible for the isoform-specific pathogenic effects of Tau in neurons that have previously been reported by us and others (Vourkou et al., 2022; Buchholz et al., 2025; Zempel et al., 2017; Buchholz and Zempel, 2024b; Kosmidis et al., 2010).

Our analysis pipeline currently relies on simple image analysis using the stereotypical anatomy of an accessible tissue and the detection of cell death, as the apoptotic rate is minor in this tissue during physiological conditions except for specific small hotspots (Milán et al., 1997; Matamoro-Vidal et al., 2024). The availability of multiple Gal4 drivers that target other traceable compartments of the wing such as the anterior (*cubitus interruptus*) or dorsal (*apterous*) compartments, as well as the capacity to integrate different targets and expression of genes of interest thanks to the combination of multiple expression systems add further versatility to the platform (Tripathi and Irvine, 2022; Zirin et al., 2024). This repertoire of tools can be extended to interrogate multiple aspects

of cell biology, for which this system has been widely used for decades, including endocytosis/intracellular trafficking (Moreno et al., 2022; Gao et al., 2017) and proteostasis (Joy et al., 2021), which are emerging areas of research in Tau pathology and its propagation (Yan and Zheng, 2021; Zhao et al., 2021; Papanikolopoulou and Skoulakis, 2020).

Disease-relevant mechanisms mediate Tau toxicity in the wing

Alongside the experimental advantages, the key highlight of the wing system is that it recapitulates many features of human Tau-related neurodegeneration. Much like in neuronal models, phosphorylation also plays a major role in promoting human Tau-induced toxicity in the wing. This is exemplified by the behaviour of the phosphomimic E14 variant (Hoover et al., 2010), which exacerbates the toxicity of two different human Tau isoforms (Figs 4 and 5). It is also further supported by the suppression of toxicity attributed to the hypophosphorylated hTau2N4R^{S2A} variant (Fig. 6) (Chatterjee et al., 2009). However, and consistent with observations by us and others in the *Drosophila* neurons (Cooper et al., 2024 preprint; Passarella and Goedert, 2018), the presence of the VQIVYK aggregation motif is essential to drive toxicity for both hTau0N4R and hTau2N4R isoforms (Figs 4 and 5). Indeed, we confirmed in our new system that the hexapeptide deletion can completely overcome the pathogenic effects of mimicking phosphorylation at 14 GSK3 β sites in hTau2N4R, rendering this variant (hTau2N4R^{E14,AVQIVYK}) inert, exactly as is the case in the *Drosophila* central nervous system (Cooper et al., 2024 preprint). The complete rescue observed with hTau0N4R^{AVQIVYK} is consistent with the finding that the C-terminal half of this isoform (which contains this domain) is required to drive toxicity in the wing margin tissue (Bougé and Parmentier, 2016). Interestingly, whereas the deletion of VQIVYK domain caused a 100% suppression of E14 toxicity, the deletion of the VQIINK aggregation-promoting domain, which is found exclusively in the 4R hTau isoforms, rescued ~80% of hTau2N4R^{E14}-driven toxicity (Fig. 5) (Seidler et al., 2018). The capacity of the two VQ motifs to promote Tau aggregation differs depending on their molecular context *in vitro*, but both have been found to contribute to aggregation *in vivo* (Macdonald et al., 2019; Wu et al., 2022; Seidler et al., 2018; Ganguly et al., 2015). Adding to this growing literature, our data in the *Drosophila* wing system highlight the importance of targeting these two motifs as promising therapeutics to counteract Tau toxicity (Aggidis et al., 2024) and our platform as a fast and high-throughput platform to enable this.

The enhanced toxicity of the clinically relevant R406W variant and its rescue upon the non-phosphorylatable S262 and S356 residues (Fig. 6) provides further evidence that the *Drosophila* wing can recapitulate the requirement of specific phospho-epitopes in Tau-mediated neurodegeneration (Parra Bravo et al., 2024; Chatterjee et al., 2009). Furthermore, these data show that the system can be used as an appropriate *in vivo* platform for understanding the pathogenic significance of multiple post-translational modifications of Tau protein that may mediate disease mechanisms (Min et al., 2015; Wada et al., 2024; Losev et al., 2021; Ait-Bouziad et al., 2020; Acosta et al., 2022).

Drosophila wing as a tool for drug discovery

Our findings that the neuroprotective peptide NAP (Leker et al., 2002; Oz et al., 2012, 2014; Quraishe et al., 2013) reduces the toxicity of hTau0N4R in our experimental paradigm (Fig. 3) demonstrates the utility of our system for screening Tau-targeting

drugs. The easy observation of the highly stereotypical adult wing, which supports further anatomical analysis (Sonnenschein et al., 2015), lends itself to high-throughput screening of multiple drug panels. The advantages of *Drosophila* as an animal model have facilitated its employment in screenings related to cancer, inflammatory bowel disease and diabetes, among others (La Marca et al., 2023; Richardson et al., 2015; Munnik et al., 2022; Xiu et al., 2022; Willoughby et al., 2013; Lagunas-Rangel et al., 2023). The wing model itself has been used as a successful platform for drug discovery and validation of EGFR inhibitors and modulators of metabolic diseases (Aritakula and Ramasamy, 2008; Bai et al., 2018; Merigliano et al., 2018).

Limitations of the model

Although this experimental platform recapitulates many aspects of Tau neurotoxicity and can therefore be used as a medium- to high-throughput tool for screening disease mechanisms and drug discovery, it is not devoid of limitations. The non-neuronal nature of the wing cells requires validation of prioritized candidates from all new screening studies in the adult nervous system. Fortunately, the genetic tools employed in the wing are directly transferrable to the adult brain, making this validation straightforward. Although it is attractive that experiments in the wing can be conducted within days, this nonetheless represents another limitation of the system, in that it does not enable us to study the impact of ageing in any Tau-related phenotypes. The adult wing nonetheless can be subjected to ageing if one wanted to assess the effect of Tau with increasing age, because this organ can show age-dependent worsening of other phenotypes, including neurodegeneration of the axons in the anterior margin (Luo et al., 2025; Lane et al., 2014; Anh et al., 2011).

Conclusion

In conclusion, our study presents a novel platform to dissect mechanisms of disease underpinning neurodegeneration in tauopathies. This highly accessible and versatile system can support Tau researchers in assessing factors that promote or reduce the pathological potential of the microtubule-associated protein, finding new interactors that mediate these effects, or exploring drug targets in a more efficient and affordable manner.

MATERIALS AND METHODS

Drosophila genetics and husbandry

Drosophila melanogaster flies were reared on standard media at 25°C. To express tools of interest, the Gal4/UAS system was employed (Brand and Perrimon, 1993) to drive expression at the posterior wing compartment using *en*-Gal4. All human Tau lines used (isoforms and variants) were tagged with N-terminal mCherry. New human Tau transgenic lines were produced by the Allan Laboratory (University of British Columbia) by fusing hTau sequences downstream of 10XUAS sequences and insertion into *attP40* (position 25C on chromosome II) to minimize position effect variegation. Human Tau isoform and variant cDNAs were subcloned using the BgIII site at the pCaU4B2G10XU plasmid using Gibson Assembly (NEB). Injection and establishment of stable transgenic lines were completed by GenomeProlab (Montreal, Canada). Precise transgenic lines and constructs are detailed in Table S4.

Drug assays

NAPVSIPQ (NAP; davunetide) (Peptide Protein Research, Fareham, UK) was added to fly food at concentrations of 5 μ g/ml or 25 μ g/ml.

Wing disc dissection and immunostaining

Third-instar larvae (~144 h after egg laying at 25°C) were dissected in PBS. Cuticles with attached imaginal discs were fixed for 20 min with 4% paraformaldehyde (Electron Microscopy Sciences, 15713-S) in PBS at

room temperature, then washed with PBS with 0.1% Triton X-100 (PBST; Merck, X100-1L). Cuticles were blocked for 45 min with 1% normal goat serum (NGS; Merck, G9023-10ML) in PBST at room temperature, and incubated with primary antibodies in PBST overnight at 4°C with constant agitation. The following day, cuticles were washed with PBST, incubated with secondary antibodies with 1% NGS in PBST for 2 h at room temperature and washed with PBST, then transferred to PBS for wind disc extraction. Discs were transferred to the microscope slide and mounted in Prolong Glass (Invitrogen, P36980) and equilibrated for 72 h in the dark at room temperature before imaging. All antibodies and concentrations used are listed in Table S4.

Adult wing imaging

Male adult flies were frozen upon collection up to 48 h after hatching. Wings were removed and imaged using a Leica stereoscopic microscope (LAS Software).

Fluorescence microscopy

Wing discs were imaged using an inverted Leica SP8 confocal microscope using a 20×/0.75 NA (whole wing disc) or 63×/1.3 NA (magnified apical sections) objective. Images of the whole wing pouch section depicted in Fig. 2B were acquired using a Leica STELLARIS 5 system (40×/1.25 NA).

Image processing and analysis

Compartment size (wing discs and adult wings)

Z-stacks of the wing discs were projected using ‘Maximum intensity’ algorithm in Fiji and used to measure the area of the posterior compartment (mCherry⁺ signal) and the whole disc [E-cadherin (E-cad; also known as Shg)⁺ silhouette] with the selection tool. Anterior compartment area was calculated by subtracting the two measures in Excel, with which the posterior/anterior area ratio was also calculated. The compartment ratio in the adult wing was measured using the L4 vein as the compartmental border, which was placed posterior to the actual and comparatively irregular border (Hama et al., 1990), calculating the anterior area again via subtraction from the whole wing surface, before obtaining the posterior/anterior area ratio.

Cell death

Z-stacks of six slices corresponding to the basal region of the wing discs were projected using the average intensity method in Fiji. mCherry and anti-E-cad antibody signals were used to generate masks of the posterior and whole wing disc pouch using the central hinge/hinge (H/H) fold as the dorsal edge. For quantification of apoptosis at the whole pouch (Fig. S1), only the H/H fold detected with anti-E-cad antibody was used. Dcp-1 signal was processed with an automatic image script in MATLAB. Briefly, the image was smoothed using Gauss filtering, and a background image was creating using rolling ball structural elements to perform a partial background subtraction. The resulting image was binarized using automatic threshold, and the signal corresponding to the anterior and posterior compartments of the pouch was isolated using the existing region masks. Percentage of apoptotic area per compartment was obtained using the Regionprops function, and the excess posterior compartment apoptosis was calculated by subtracting the percentages within each compartment.

JNK signalling

Z-stacks of six slices spanning the apical region of the wing disc proper at the dorsal region of the pouch were projected using the ‘average intensity’ in Fiji. LacZ intensity was read three times at both the anterior and posterior compartments (the latter identified by the signal of mCherry::hTau) to obtain averages that were used to obtain the posterior/anterior ratio for LacZ signal.

Other processing

Images of the whole discs (e.g. Fig. 1B) were generated with the ‘maximum projection’ algorithm in Fiji. Sagittal projections (Fig. 2B) were made using the ‘reslice’ tool in Fiji, with a maximum projection of 3.78 μm. Images of the dorsal (apoptosis) or apical (JNK signalling) regions corresponded to representative images of the same averaged projections used for the analyses. Representative images were subjected to minimum modification

using Fiji, such as rotation, cropping or automated adjustment of brightness and contrast of the whole view for optimal presentation.

Statistical analyses

Statistical analyses were performed in Prism 10 (GraphPad) and Python (SciPy library). All the datasets were tested for normality using the Shapiro–Wilk test. Nonparametric tests were used when at least one sample did not display normal distribution, and appropriate corrections were applied if the assumption of equality of s.d. was not met. For commonly used tests, such as the *t*-test, two-tailed versions were used. Figure legends include information about precise *n* numbers, presented data and the type of statistical test, with all the individual datapoints presented in the graphs. All data points are presented using violin plots, which display the median as well as the 25th and 75th quartiles. *P*<0.05 was considered significant.

Posterior:anterior compartment size ratio

Posterior:anterior compartment size ratios of larval wing discs and adult wings expressing UAS-driven constructs were compared using the Brown–Forsythe and Welch ANOVA test or the Kruskal–Wallis test when normality conditions were not met for at least one of the samples.

Apoptotic area

The excess Dcp-1-positive surface at the posterior compartment was compared between genotypes using the Brown–Forsythe and Welch ANOVA test (Kruskal–Wallis test for samples not following normal distribution). Paired comparisons found in Tables S2 and S3 were done with Student’s (normal and equal variance samples) or Welch’s (normal and unequal variances) *t*-test (Mann–Whitney *U* test for samples not following normal distribution). Additionally, each sample was tested against 0 (no difference in apoptotic area between anterior and posterior compartment) using the one-sample *t*-test (one-sample Wilcoxon test for samples not following normal distribution).

puc-LacZ intensity

Posterior:anterior ratio of β-galactosidase antibody signal was compared between genotypes using the Kruskal–Wallis test.

Acknowledgements

We thank Natalia Bulgakova for fly reagents. We thank the Imaging and Microscopy Centre at the University of Southampton School of Biological Sciences and the technical staff at the invertebrate facility for their support and assistance. We further thank the members of the Mudher laboratory and the School of Biological Sciences for their feedback on the project and manuscript.

Competing interests

The authors declare no competing or financial interests.

Author contributions

Conceptualization: M.R.-M., E.M.C.S., D.W.A., A.M.; Data curation: M.R.-M.; Formal analysis: M.R.-M., A.S.C.; Funding acquisition: D.W.A., A.M.; Investigation: M.R.-M., A.S.C., T.L., J.L., S.A.; Methodology: M.R.-M., A.S.C., T.L., J.L., S.A., E.M.C.S., D.W.A.; Project administration: M.R.-M., A.M.; Resources: M.R.-M., A.S.C., T.L., J.L., S.A., L.S., D.W.A., A.M.; Software: M.R.-M., D.W.A.; Supervision: E.M.C.S., D.W.A., A.M.; Validation: M.R.-M., A.S.C., T.L., J.L., S.A.; Visualization: M.R.-M., A.S.C., E.M.C.S.; Writing – original draft: M.R.-M., A.M.; Writing – review & editing: M.R.-M., L.S., D.W.A., A.M.

Funding

This work was supported by a grant from the Alzheimer’s Society (575, AS-PG-21-033) awarded to A.M. A.S.C. was supported by a PhD studentship from the Gerald Kerut Charitable Trust awarded to A.M. Fly transgenesis was supported by grants from the Alzheimer Society of Canada (Proof of Concept grant ALZSOCCA, 2020) and University of British Columbia Centre for Brain Health (Alzheimer’s Disease Research Grant UBCCBH 2023), both awarded to D.W.A. Open Access funding provided by University of Southampton. Deposited in PMC for immediate release.

Data and resource availability

The generated *Drosophila* strains are available upon request. Custom automated scripts are available at https://github.com/miguelramirezmoreno/toxicity_assay. All other relevant data and details of resources can be found within the article and its supplementary information.

First Person

This article has an associated First Person interview with the first author of the paper.

References

- Abreha, M. H., Ojelade, S., Dammer, E. B., McEachin, Z. T., Duong, D. M., Gearing, M., Bassell, G. J., Lah, J. J., Levey, A. I., Shulman, J. M. et al. (2021). TBK1 interacts with tau and enhances neurodegeneration in tauopathy. *J. Biol. Chem.* **296**, 100760. doi:10.1016/j.jbc.2021.100760
- Acosta, D. M., Mancinelli, C., Bracken, C. and Eliezer, D. (2022). Post-translational modifications within tau paired helical filament nucleating motifs perturb microtubule interactions and oligomer formation. *J. Biol. Chem.* **298**, 101442. doi:10.1016/j.jbc.2021.101442
- Aggdis, A., Devitt, G., Zhang, Y., Chatterjee, S., Townsend, D., Fullwood, N. J., Ortega, E. R., Tarutani, A., Hasegawa, M., Cooper, A. et al. (2024). A novel peptide-based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies. *Alzheimers Dement.* **20**, 7788-7804. doi:10.1002/alz.14246
- Ait-Bouziad, N., Chiki, A., Limorenko, G., Xiao, S., Eliezer, D. and Lashuel, H. A. (2020). Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of Tau. *J. Biol. Chem.* **295**, 7905-7922. doi:10.1074/jbc.RA119.012517
- Alonso, A. C., Zaidi, T., Novak, M., Grundke-Iqbal, I. and Iqbal, K. (2001). Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. *Proc. Natl. Acad. Sci. USA* **98**, 6923-6928. doi:10.1073/pnas.121119298
- Alzheimer, A. (1907). Über eigenartige Erkrankung der Hirnrinde. *All. Z. Psychiatr.* **64**, 146-148.
- Anh, N. T. T., Nishitani, M., Harada, S., Yamaguchi, M. and Kamei, K. (2011). Essential role of Duox in stabilization of Drosophila wing. *J. Biol. Chem.* **286**, 33244-33251. doi:10.1074/jbc.M111.263178
- Aritakula, A. and Ramasamy, A. (2008). Drosophila-based in vivo assay for the validation of inhibitors of the epidermal growth factor receptor/Ras pathway. *J. Biosci.* **33**, 731-742. doi:10.1007/s12038-008-0093-9
- Arnés, M., Casas-Tintó, S., Malmendal, A. and Ferrús, A. (2017). Amyloid β 2 peptide is toxic to non-neural cells in Drosophila yielding a characteristic metabolite profile and the effect can be suppressed by PI3K. *Biol. Open* **6**, 1664-1671. doi:10.1242/bio.029991
- Asada-Utsugi, M., Uemura, K., Ayaki, T., T. Uemura, M., Minamiyama, S., Hikami, R., Morimura, T., Shodai, A., Ueki, T., Takahashi, R. et al. (2022). Failure of DNA double-strand break repair by tau mediates Alzheimer's disease pathology in vitro. *Commun. Biol.* **5**, 358. doi:10.1038/s42003-022-03312-0
- Bachmann, S., Bell, M., Klimek, J. and Zempel, H. (2021). Differential effects of the six human TAU isoforms: somatic retention of 2N-TAU and increased microtubule number induced by 4R-TAU. *Front. Neurosci.* **15**, 643115. doi:10.3389/fnins.2021.643115
- Bai, Y., Li, K., Shao, J., Luo, Q. and Jin, L. H. (2018). Flos Chrysanthemii Indici extract improves a high-sucrose diet-induced metabolic disorder in Drosophila. *Exp. Ther. Med.* **16**, 2564-2572. doi:10.3892/etm.2018.6470
- Bassan, M., Zamostiano, R., Davidson, A., Pinhasov, A., Giladi, E., Perl, O., Bassan, H., Blat, C., Gibney, G., Glazner, G. et al. (1999). Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. *J. Neurochem.* **72**, 1283-1293. doi:10.1046/j.1471-4159.1999.0721283.x
- Beira, J. V. and Paro, R. (2016). The legacy of Drosophila imaginal discs. *Chromosoma* **125**, 573-592. doi:10.1007/s00412-016-0595-4
- Bergantiños, C., Corominas, M. and Serras, F. (2010). Cell death-induced regeneration in wing imaginal discs requires JNK signalling. *Development* **137**, 1169-1179. doi:10.1242/dev.045559
- Bougé, A.-L. and Parmentier, M.-L. (2016). Tau excess impairs mitosis and kinesin-5 function, leading to aneuploidy and cell death. *Dis. Model. Mech.* **9**, 307-319. doi:10.1242/dmm.022558
- Brand, A. H. and Perrimon, N. (1993). Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* **118**, 401-415. doi:10.1242/dev.118.2.401
- Buchholz, S. and Zempel, H. (2024a). The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes. *Alzheimers Dement.* **20**, 3606-3628. doi:10.1002/alz.13784
- Buchholz, S. and Zempel, H. (2024b). Suppression of mature TAU isoforms prevents Alzheimer's disease-like amyloid-beta oligomer-induced spine loss in rodent neurons. *Neural Regeneration Research* **19**, 1655-1657. doi:10.4103/1673-5374.389644
- Buchholz, S., Kabbani, M. A. A., Bell-Simons, M., Kluge, L., Cagmak, C., Klimek, J., Haag, N., Iohan, L. C., Coulon, A., Costa, M. R. et al. (2025). The tau isoform 1N4R confers vulnerability of MAPT knockout human iPSC-derived neurons to amyloid beta and phosphorylated tau-induced neuronal dysfunction. *Alzheimer's Dement.* **21**, e14403. doi:10.1002/alz.14403
- Cario, A., Savastano, A., Wood, N. B., Liu, Z., Previsto, M. J., Hendricks, A. G., Zweckstetter, M. and Berger, C. L. (2022). The pathogenic R5L mutation disrupts formation of Tau complexes on the microtubule by altering local N-terminal structure. *Proc. Natl. Acad. Sci. USA* **119**, e2114215119. doi:10.1073/pnas.2114215119
- Chakraborty, R., Li, Y., Zhou, L. and Golic, K. G. (2015). Corp regulates P53 in Drosophila melanogaster via a negative feedback loop. *PLoS Genet.* **11**, e1005400. doi:10.1371/journal.pgen.1005400
- Chatterjee, S., Sang, T.-K., Lawless, G. M. and Jackson, G. R. (2009). Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. *Hum. Mol. Genet.* **18**, 164-177. doi:10.1093/hmg/ddn326
- Chung, P. J., Song, C., Deek, J., Miller, H. P., Li, Y., Choi, M. C., Wilson, L., Feinstein, S. C. and Safinya, C. R. (2016). Tau mediates microtubule bundle architectures mimicking fascicles of microtubules found in the axon initial segment. *Nat. Commun.* **7**, 12278. doi:10.1038/ncomms12278
- Cimini, S., Giaccone, G., Tagliavini, F., Costantino, M., Perego, P. and Rossi, G. (2022). P301L tau mutation leads to alterations of cell cycle, DNA damage response and apoptosis: evidence for a role of tau in cancer. *Biochem. Pharmacol.* **200**, 115043. doi:10.1016/j.bcp.2022.115043
- Cooper, A., Richardson, B., Ruiz Ortega, E., Zhang, Y., Batchelor, B., Vaikakkara Chithran, A., Liu, J., Lian, T., Ramirez Moreno, M., Boehme, B. et al. (2024). Aggregation promoting sequences rather than phosphorylation are essential for Tau-mediated toxicity in Drosophila. *bioRxiv* 2024.12.22.629946.
- Corsi, A., Bombieri, C., Valenti, M. T. and Romanelli, M. G. (2022). Tau isoforms: gaining insight into MAPT alternative splicing. *Int. J. Mol. Sci.* **23**, 15383. doi:10.3390/ijms232315383
- Cotman, C. W. and Anderson, A. J. (1995). A potential role for apoptosis in neurodegeneration and Alzheimer's disease. *Mol. Neurobiol.* **10**, 19-45. doi:10.1007/BF02740836
- Cowan, C. M., Bossing, T., Page, A., Shepherd, D. and Mudher, A. (2010). Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. *Acta Neuropathol.* **120**, 593-604. doi:10.1007/s00401-010-0716-8
- Cowan, C. M., Sealey, M. A., Quraishe, S., Targett, M.-T., Marcellus, K., Allan, D. and Mudher, A. (2011). Modelling tauopathies in Drosophila: insights from the fruit fly. *Int. J. Alzheimers Dis.* **2011**, 598157. doi:10.4061/2011/598157
- Dias-Santagata, D., Fulga, T. A., Duttaray, A. and Feany, M. B. (2007). Oxidative stress mediates tau-induced neurodegeneration in Drosophila. *J. Clin. Invest.* **117**, 236-245. doi:10.1172/JCI28769
- Diaz-Garcia, S., Ahmed, S. and Baonza, A. (2016). Analysis of the function of apoptosis during imaginal wing disc regeneration in Drosophila melanogaster. *PLoS ONE* **11**, e0165554. doi:10.1371/journal.pone.0165554
- Drechsel, D. N., Hyman, A. A., Cobb, M. H. and Kirschner, M. W. (1992). Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. *Mol. Biol. Cell* **3**, 1141-1154. doi:10.1091/mbc.3.10.1141
- Farmer, K. M., Ghag, G., Puangmalai, N., Montalbano, M., Bhatt, N. and Kaye, R. (2020). P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer's disease. *Acta Neuropathol. Commun.* **8**, 132. doi:10.1186/s40478-020-01012-6
- Fossgreen, A., Brückner, B., Czech, C., Masters, C. L., Beyreuther, K. and Paro, R. (1998). Transgenic Drosophila expressing human amyloid precursor protein show gamma-secretase activity and a blistered-wing phenotype. *Proc. Natl. Acad. Sci. USA* **95**, 13703-13708. doi:10.1073/pnas.95.23.13703
- Frost, B. (2023). Alzheimer's disease and related tauopathies: disorders of disrupted neuronal identity. *Trends Neurosci.* **46**, 797-813. doi:10.1016/j.tins.2023.07.006
- Ganguly, P., Do, T. D., Larini, L., Lapointe, N. E., Sercel, A. J., Shade, M. F., Feinstein, S. C., Bowers, M. T. and Shea, J.-E. (2015). Tau assembly: the dominant role of PHF6 (VQIVYK) in microtubule binding region repeat R3. *J. Phys. Chem. B* **119**, 4582-4593. doi:10.1021/acs.jpcc.5b00175
- Gao, H., He, F., Lin, X. and Wu, Y. (2017). Drosophila VAMP7 regulates Wingless intracellular trafficking. *PLoS ONE* **12**, e0186938. doi:10.1371/journal.pone.0186938
- Garcia-Bellido, A., Ripoll, P. and Morata, G. (1973). Developmental compartmentalisation of the wing disk of Drosophila. *Nat. New Biol.* **245**, 251-253. doi:10.1038/newbio245251a0
- Gistelincq, M., Lambert, J.-C., Callaerts, P., Deraut, B. and Dourlen, P. (2012). Drosophila models of tauopathies: what have we learned? *Int. J. Alzheimer's Dis.* **2012**, 970980. doi:10.1155/2012/970980
- Goedert, M. and Jakes, R. (2005). Mutations causing neurodegenerative tauopathies. *Biochim. Biophys. Acta Mol. Basis Dis.* **1739**, 240-250. doi:10.1016/j.bbadis.2004.08.007
- Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D. and Crowther, R. A. (1989). Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. *Neuron* **3**, 519-526. doi:10.1016/0896-6273(89)90210-9
- Goedert, M., Crowther, R. A., Scheres, S. H. W. and Spillantini, M. G. (2023). Tau and neurodegeneration. *Cytoskeleton* **81**, 95-102. doi:10.1002/cm.21812
- Goode, B. L., Chau, M., Denis, P. E. and Feinstein, S. C. (2000). Structural and functional differences between 3-repeat and 4-repeat tau isoforms: implications for normal tau function and the onset of neurodegenerative disease. *J. Biol. Chem.* **275**, 38182-38189. doi:10.1074/jbc.M007489200

- Gozes, I., Morimoto, B. H., Tiong, J., Fox, A., Sutherland, K., Dangoor, D., Holser-Cochav, M., Vered, K., Newton, P., Aisen, P. S. et al. (2005). NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). *CNS Drug Rev.* **11**, 353-368. doi:10.1111/j.1527-3458.2005.tb00053.x
- Hama, C., Ali, Z. and Kornberg, T. B. (1990). Region-specific recombination and expression are directed by portions of the *Drosophila* engrailed promoter. *Genes Dev.* **4**, 1079-1093. doi:10.1101/gad.4.7.1079
- Handke, B., Szabad, J., Lidsky, P. V., Hafen, E. and Lehner, C. F. (2014). Towards long term cultivation of *Drosophila* wing imaginal discs in vitro. *PLoS ONE* **9**, e107333. doi:10.1371/journal.pone.0107333
- Hatch, R. J., Wei, Y., Xia, D. and Götz, J. (2017). Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment. *Acta Neuropathol.* **133**, 717-730. doi:10.1007/s00401-017-1674-1
- Hooper, C., Meimaridou, E., Tavassoli, M., Melino, G., Lovestone, S. and Killick, R. (2007). p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. *Neurosci. Lett.* **418**, 34-37. doi:10.1016/j.neulet.2007.03.026
- Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitsick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L. et al. (2010). Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. *Neuron* **68**, 1067-1081. doi:10.1016/j.neuron.2010.11.030
- Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A. et al. (1998). Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* **393**, 702-705. doi:10.1038/31508
- Jazvinščak Jembrek, M., Slade, N., Hof, P. R. and Šimić, G. (2018). The interactions of p53 with tau and Aβ as potential therapeutic targets for Alzheimer's disease. *Prog. Neurobiol.* **168**, 104-127. doi:10.1016/j.pneurobio.2018.05.001
- Joy, J., Barrio, L., Santos-Tapia, C., Romão, D., Giakoumakis, N. N., Clemente-Ruiz, M. and Milán, M. (2021). Proteostasis failure and mitochondrial dysfunction leads to aneuploidy-induced senescence. *Dev. Cell* **56**, 2043-2058.e7. doi:10.1016/j.devcel.2021.06.009
- Kanaan, N. M. (2023). Tau here, tau there, tau almost everywhere: clarifying the distribution of tau in the adult CNS. *Cytoskeleton* **81**, 107-115. doi:10.1002/cm.21820
- Kanaan, N. M., Morfini, G., Pigino, G., Lapointe, N. E., Andreadis, A., Song, Y., Leitman, E., Binder, L. I. and Brady, S. T. (2012). Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. *Neurobiol. Aging* **33**, 826.e15-826.e30. doi:10.1016/j.neurobiolaging.2011.06.006
- Khurana, V. and Feany, M. B. (2007). Connecting cell-cycle activation to neurodegeneration in *Drosophila*. *Biochim. Biophys. Acta Mol. Basis Dis.* **1772**, 446-456. doi:10.1016/j.bbadis.2006.10.007
- Kimura, T., Sharma, G., Ishiguro, K. and Hisanaga, S.-I. (2018). Phospho-Tau bar code: analysis of phosphoisotypes of tau and its application to tauopathy. *Front. Neurosci.* **12**, 44. doi:10.3389/fnins.2018.00044
- Kosmidis, S., Grammenoudi, S., Papanikolopoulou, K. and Skoulakis, E. M. C. (2010). Differential effects of Tau on the integrity and function of neurons essential for learning in *Drosophila*. *J. Neurosci.* **30**, 464-477. doi:10.1523/JNEUROSCI.1490-09.2010
- La Marca, J. E., Ely, R. W., Diepstraten, S. T., Burke, P., Kelly, G. L., Humbert, P. O. and Richardson, H. E. (2023). A *Drosophila* chemical screen reveals synergistic effect of MEK and DGKα inhibition in Ras-driven cancer. *Dis. Model. Mech.* **16**, dmm049769. doi:10.1242/dmm.049769
- Lagunas-Rangel, F. A., Liao, S., Williams, M. J., Trukhan, V., Fredriksson, R. and Schiöth, H. B. (2023). *Drosophila* as a rapid screening model to evaluate the hypoglycemic effects of dipeptidyl peptidase 4 (DPP4) inhibitors: high evolutionary conservation of DPP4. *Biomedicines* **11**, 3032. doi:10.3390/biomedicines11113032
- Lane, S. J., Frankino, W. A., Elekonich, M. M. and Roberts, S. P. (2014). The effects of age and lifetime flight behavior on flight capacity in *Drosophila melanogaster*. *J. Exp. Biol.* **217**, 1437-1443. doi:10.1242/jeb.095646
- Leker, R. R., Teichner, A., Grigoriadis, N., Ovadia, H., Breneman, D. E., Fridkin, M., Giladi, E., Romano, J. and Gozes, I. (2002). Nap, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. *Stroke* **33**, 1085-1092. doi:10.1161/01.STR.0000014207.05597.D7
- Li, H.-L., Wang, H.-H., Liu, S.-J., Deng, Y.-Q., Zhang, Y.-J., Tian, Q., Wang, X.-C., Chen, X.-Q., Yang, Y., Zhang, J.-Y. et al. (2007). Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. *Proc. Natl. Acad. Sci. USA* **104**, 3591-3596. doi:10.1073/pnas.0609303104
- Liu, C. and Götz, J. (2013). Profiling murine tau with 0n, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus. *PLoS ONE* **8**, e84849. doi:10.1371/journal.pone.0084849
- Liu, C., Song, X., Nisbet, R. and Götz, J. (2016). Co-immunoprecipitation with Tau Isoform-specific Antibodies Reveals Distinct Protein Interactions and Highlights a Putative Role for 2N Tau in Disease. *J. Biol. Chem.* **291**, 8173-8188. doi:10.1074/jbc.M115.641902
- Lopez-Gonzalez, R., Yang, D., Pribadi, M., Kim, T. S., Krishnan, G., Choi, S. Y., Lee, S., Coppola, G. and Gao, F.-B. (2019). Partial inhibition of the overactivated Ku80-dependent DNA repair pathway rescues neurodegeneration in C9ORF72-ALS/FTD. *Proc. Natl. Acad. Sci. USA* **116**, 9628-9633. doi:10.1073/pnas.1901313116
- Losev, Y., Frenkel-Pinter, M., Abu-Hussien, M., Viswanathan, G. K., Elyashiv-Revivo, D., Gerles, R., Khalaila, I., Gazit, E. and Segal, D. (2021). Differential effects of putative N-glycosylation sites in human Tau on Alzheimer's disease-related neurodegeneration. *Cell. Mol. Life Sci.* **78**, 2231-2245. doi:10.1007/s00018-020-03643-3
- Luo, J., Qiu, Y., Pan, Y., Xu, R., Sun, Y., Sun, Y., Zhuang, L., Xue, E., Li, W., Zhou, Q. et al. (2025). APP induces AICD-mediated autophagy-dependent axon degeneration. *Aging Cell* e70301. doi:10.1111/acel.70301
- Macdonald, J. A., Bronner, I. F., Drynan, L., Fan, J., Curry, A., Fraser, G., Lavenir, I. and Goedert, M. (2019). Assembly of transgenic human P301S Tau is necessary for neurodegeneration in murine spinal cord. *Acta Neuropathol. Commun.* **7**, 44. doi:10.1186/s40478-019-0695-5
- Mandelkow, E. M. and Mandelkow, E.-M. (2012). Biochemistry and cell biology of tau protein in neurofibrillary degeneration. *Cold Spring Harb. Perspect. Med.* **2**, a006247. doi:10.1101/cshperspect.a006247
- Martín-Blanco, E., Gampel, A., Ring, J., Virdee, K., Kirov, N., Tolkovsky, A. M. and Martínez-Arias, A. (1998). puckered encodes a phosphatase that mediates a feedback loop regulating JNK activity during dorsal closure in *Drosophila*. *Genes Dev.* **12**, 557-570. doi:10.1101/gad.12.4.557
- Matamoro-Vidal, A., Cumming, T., Davidović, A., Levillayer, F. and Levayer, R. (2024). Patterned apoptosis has an instructive role for local growth and tissue shape regulation in a fast-growing epithelium. *Curr. Biol.* **34**, 376-388.e7. doi:10.1016/j.cub.2023.12.031
- Méphon-Gaspard, A., Boca, M., Pioche-Durieu, C., Desforges, B., Burgo, A., Hamon, L., Piétrement, O. and Pastré, D. (2016). Role of tau in the spatial organization of axonal microtubules: keeping parallel microtubules evenly distributed despite macromolecular crowding. *Cell. Mol. Life Sci.* **73**, 3745-3760. doi:10.1007/s00018-016-2216-z
- Merigliano, C., Mascolo, E., La Torre, M., Saggio, I. and Verni, F. (2018). Protective role of vitamin B6 (PLP) against DNA damage in *Drosophila* models of type 2 diabetes. *Sci. Rep.* **8**, 11432. doi:10.1038/s41598-018-29801-z
- Milán, M., Campuzano, S. and García-Bellido, A. (1997). Developmental parameters of cell death in the wing disc of *Drosophila*. *Proc. Natl. Acad. Sci. USA* **94**, 5691-5696. doi:10.1073/pnas.94.11.5691
- Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., Shirakawa, K., Minami, S. S., Defensor, E., Mok, S. A. et al. (2015). Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. *Nat. Med.* **21**, 1154-1162. doi:10.1038/nm.3951
- Moreno, M. R., Boswell, K., Casbolt, H. L. and Bulgakova, N. A. (2022). Multifaceted control of E-cadherin dynamics by Adaptor Protein Complex 1 during epithelial morphogenesis. *Mol. Biol. Cell* **33**, ar80. doi:10.1091/mbc.E21-12-0598
- Morris, M., Maeda, S., Vossel, K. and Mucke, L. (2011). The many faces of Tau. *Neuron* **70**, 410-426. doi:10.1016/j.neuron.2011.04.009
- Munnik, C., Xaba, M. P., Malindisa, S. T., Russell, B. L. and Sooklal, S. A. (2022). *Drosophila melanogaster*: a platform for anticancer drug discovery and personalized therapies. *Front. Genet.* **13**, 949241. doi:10.3389/fgenet.2022.949241
- Oz, S., Ivashko-Pachima, Y. and Gozes, I. (2012). The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. *PLoS ONE* **7**, e51458. doi:10.1371/journal.pone.0051458
- Oz, S., Kapitansky, O., Ivashco-Pachima, Y., Malishkevich, A., Giladi, E., Skalka, N., Rosin-Arbesfeld, R., Mittelman, L., Segev, O., Hirsch, J. A. et al. (2014). The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. *Mol. Psychiatry* **19**, 1115-1124. doi:10.1038/mp.2014.97
- Papanikolopoulou, K. and Skoulakis, E. M. C. (2020). Altered proteostasis in neurodegenerative tauopathies. *Adv. Exp. Med. Biol.* **1233**, 177-194. doi:10.1007/978-3-030-38266-7_7
- Parra Bravo, C., Naguib, S. A. and Gan, L. (2024). Cellular and pathological functions of tau. *Nat. Rev. Mol. Cell Biol.* **25**, 845-864. doi:10.1038/s41580-024-00753-9
- Passarella, D. and Goedert, M. (2018). Beta-sheet assembly of Tau and neurodegeneration in *Drosophila melanogaster*. *Neurobiol. Aging* **72**, 98-105. doi:10.1016/j.neurobiolaging.2018.07.022
- Pérez-Garijo, A., Shlevkov, E. and Morata, G. (2009). The role of Dpp and Wg in compensatory proliferation and in the formation of hyperplastic overgrowths caused by apoptotic cells in the *Drosophila* wing disc. *Development* **136**, 1169-1177. doi:10.1242/dev.034017
- Pérez-Garijo, A., Fuchs, Y. and Steller, H. (2013). Apoptotic cells can induce non-autonomous apoptosis through the TNF pathway. *eLife* **2**, e01004. doi:10.7554/eLife.01004
- Pinal, N., Calleja, M. and Morata, G. (2019). Pro-apoptotic and pro-proliferation functions of the JNK pathway of *Drosophila*: roles in cell competition, tumorigenesis and regeneration. *Open Biol.* **9**, 180256. doi:10.1098/rsob.180256

- Prezel, E., Elie, A., Delaroché, J., Stoppin-Mellet, V., Bosc, C., Serre, L., Fourest-Lieuvin, A., Andrieux, A., Vantard, M. and Arnal, I. (2018). Tau can switch microtubule network organizations: from random networks to dynamic and stable bundles. *Mol. Biol. Cell* **29**, 154-165. doi:10.1091/mbc.E17-06-0429
- Quraishe, S., Cowan, C. M. and Mudher, A. (2013). NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. *Mol. Psychiatry* **18**, 834-842. doi:10.1038/mp.2013.32
- Quraishe, S., Sealey, M., Cranfield, L. and Mudher, A. (2016). Microtubule stabilising peptides rescue tau phenotypes *in-vivo*. *Sci. Rep.* **6**, 38224. doi:10.1038/srep38224
- Rauch, J. N., Luna, G., Guzman, E., Audouard, M., Challis, C., Sibih, Y. E., Leshuk, C., Hernandez, I., Wegmann, S., Hyman, B. T. et al. (2020). LRP1 is a master regulator of tau uptake and spread. *Nature* **580**, 381-385. doi:10.1038/s41586-020-2156-5
- Richardson, H. E., Willoughby, L. and Humbert, P. O. (2015). Screening for anti-cancer drugs in Drosophila. *eLife*. doi:10.1002/9780470015902.a0022535
- Ring, J. M. and Martinez Arias, A. (1993). puckered, a gene involved in position-specific cell differentiation in the dorsal epidermis of the Drosophila larva. *Dev. Suppl.* **251-259**. doi:10.1242/dev.119.Supplement.251
- Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., Gonen, T. and Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. *Nat. Chem.* **10**, 170-176. doi:10.1038/nchem.2889
- Sivanantharajah, L., Mudher, A. and Shepherd, D. (2019). An evaluation of Drosophila as a model system for studying tauopathies such as Alzheimer's disease. *J. Neurosci. Methods* **319**, 77-88. doi:10.1016/j.jneumeth.2019.01.001
- Sola, M., Magrin, C., Pedrioli, G., Pinton, S., Salvadè, A., Papin, S. and Paganetti, P. (2020). Tau affects P53 function and cell fate during the DNA damage response. *Commun. Biol.* **3**, 245. doi:10.1038/s42003-020-0975-4
- Song, Z., McCall, K. and Steller, H. (1997). DCP-1, a Drosophila cell death protease essential for development. *Science* **275**, 536-540. doi:10.1126/science.275.5299.536
- Sonnenschein, A., Vanderzee, D., Pitchers, W. R., Chari, S. and Dworkin, I. (2015). An image database of Drosophila melanogaster wings for phenomic and biometric analysis. *GigaScience* **4**, 25. doi:10.1186/s13742-015-0065-6
- Steinhilb, M. L., Dias-Santagata, D., Mulkearns, E. E., Shulman, J. M., Biernat, J., Mandelkow, E. M. and Feany, M. B. (2007). S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. *J. Neurosci. Res.* **85**, 1271-1278. doi:10.1002/jnr.21232
- Stoothoff, W. H. and Johnson, G. V. W. (2005). Tau phosphorylation: physiological and pathological consequences. *Biochim. Biophys. Acta* **1739**, 280-297. doi:10.1016/j.bbadis.2004.06.017
- Tabata, T., Schwartz, C., Gustavson, E., Ali, Z. and Kornberg, T. B. (1995). Creating a Drosophila wing de novo, the role of engrailed, and the compartment border hypothesis. *Development* **121**, 3359-3369. doi:10.1242/dev.121.10.3359
- Tabeshmehr, P. and Eftekharpour, E. (2023). Tau; one protein, so many diseases. *Biology* **12**, 244. doi:10.3390/biology12020244
- Tripathi, B. K. and Irvine, K. D. (2022). The wing imaginal disc. *Genetics* **220**, iyac020. doi:10.1093/genetics/iyac020
- Troy, C. M. and Jean, Y. Y. (2015). Caspases: therapeutic targets in neurologic disease. *Neurotherapeutics* **12**, 42-48. doi:10.1007/s13311-014-0307-9
- von Bergen, M., Friedhoff, P., Biernat, J., Heberle, J., Mandelkow, E.-M. and Mandelkow, E. (2000). Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. *Proc. Natl. Acad. Sci. USA* **97**, 5129-5134. doi:10.1073/pnas.97.10.5129
- Vourkou, E., Paspaliaris, V., Bourouliti, A., Zerva, M.-C., Prifti, E., Papanikolopoulou, K. and Skoulakis, E. M. C. (2022). Differential effects of human tau isoforms to neuronal dysfunction and toxicity in the Drosophila CNS. *Int. J. Mol. Sci.* **23**, 12985. doi:10.3390/ijms232112985
- Wada, H., Maruyama, T. and Niikura, T. (2024). SUMO1 modification of 0N4R-tau is regulated by PIASx, SENP1, SENP2, and TRIM11. *Biochem. Biophys. Res. Rep.* **39**, 101800. doi:10.1016/j.bbrep.2024.101800
- Wegmann, S., Biernat, J. and Mandelkow, E. (2021). A current view on Tau protein phosphorylation in Alzheimer's disease. *Curr. Opin. Neurobiol.* **69**, 131-138. doi:10.1016/j.conb.2021.03.003
- Weingarten, M. D., Lockwood, A. H., Hwo, S. Y. and Kirschner, M. W. (1975). A protein factor essential for microtubule assembly. *Proc. Natl. Acad. Sci. USA* **72**, 1858-1862. doi:10.1073/pnas.72.5.1858
- Willoughby, L. F., Schlosser, T., Manning, S. A., Parisot, J. P., Street, I. P., Richardson, H. E., Humbert, P. O. and Brumby, A. M. (2013). An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery. *Dis. Model. Mech.* **6**, 521-529. doi:10.1242/dmm.009985
- Wittmann, C. W., Wszolek, M. F., Shulman, J. M., Salvaterra, P. M., Lewis, J., Hutton, M. and Feany, M. B. (2001). Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. *Science* **293**, 711-714. doi:10.1126/science.1062382
- Wu, L., Madhavan, S. S., Tan, C. and Xu, B. (2022). Hexameric aggregation nucleation core sequences and diversity of pathogenic tau strains. *Pathogens* **11**, 1559. doi:10.3390/pathogens11121559
- Xiu, M., Wang, Y., Yang, D., Zhang, X., Dai, Y., Liu, Y., Lin, X., Li, B. and He, J. (2022). Using Drosophila melanogaster as a suitable platform for drug discovery from natural products in inflammatory bowel disease. *Front. Pharmacol.* **13**, 1072715. doi:10.3389/fphar.2022.1072715
- Yan, M. and Zheng, T. (2021). Role of the endolysosomal pathway and exosome release in tau propagation. *Neurochem. Int.* **145**, 104988. doi:10.1016/j.neuint.2021.104988
- Yusuff, T., Chang, Y.-C., Sang, T.-K., Jackson, G. R. and Chatterjee, S. (2023). Codon-optimized TDP-43 mediates neurodegeneration in a Drosophila model of ALS/FTLD. *Front. Genet.* **14**, 881638. doi:10.3389/fgene.2023.881638
- Zempel, H., Dennissen, F. J. A., Kumar, Y., Luedtke, J., Biernat, J., Mandelkow, E. M. and Mandelkow, E. (2017). Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture. *J. Biol. Chem.* **292**, 12192-12207. doi:10.1074/jbc.M117.784702
- Zhao, J., Wu, H. and Tang, X.-Q. (2021). Tau internalization: a complex step in tau propagation. *Ageing Res. Rev.* **67**, 101272. doi:10.1016/j.arr.2021.101272
- Zhong, Q., Congdon, E. E., Nagaraja, H. N. and Kuret, J. (2012). Tau isoform composition influences rate and extent of filament formation. *J. Biol. Chem.* **287**, 20711-20719. doi:10.1074/jbc.M112.364067
- Zirin, J., Jusiak, B., Lopes, R., Ewen-Campen, B., Bosch, J. A., Risbeck, A., Forman, C., Villalta, C., Hu, Y. and Perrimon, N. (2024). Expanding the Drosophila toolkit for dual control of gene expression. *eLife* **12**, RP94073. doi:10.7554/eLife.94073